Superior Performance of Newly Developed Alinity Anti‐HCV Next Assay in the Diagnosis of HCV Infection

Authors:

Abstract
World Health Organization recommends anti‐HCV antibody testing for primary screening to be followed by HCV‐RNA. However, current serological assays are prone to false‐positive results. We ascertained the ability of the newly developed Abbott Alinity‐i anti‐HCV Next assay (Research‐Use‐Only) to resolve false‐positives and profiled its performance edges. Samples ( n = 2186) received from January to June 2024 were subjected to anti‐HCV testing using Architect and anti‐HCV Next (Abbott), and LIAISON XL MUREX HCV antibody assays. Samples were categorized based on the signal to cutoff (S/CO) of on‐market anti‐HCV assays (Architect and Liaison) as negative Architect ( n = 1537), equivocal Architect ≥1/Liaison‐ ( n = 226), low‐positive Architect+ ≥1 to ( n = 228) and high‐positive Architect ≥8/Liaison+ ( n = 195). Hepatitis C virus core antigen (HCVcAg) and HCV‐RNA were quantified using Architect HCVcAg and Abbott real‐time PCR, respectively. Performance on seroconversion and proficiency testing panels were assessed. Significant proportion of equivocal (99%) & low‐positive (76.3%) samples were negative in Next ( p < 0.0001). The signal intensities of Next were significantly lower for true‐negative and higher for positives than the other two assays ( p < 0.0001). Next exhibited superior (10–12 days) seroconversion sensitivity (2/4 panels) and comparable performance between genotypes ( p > 0.05). Our findings suggest that the newly developed anti‐HCV Next assay is configured better to resolve challenging false‐positives and to achieve exquisite sensitivity, thereby reducing the burden/cost of retesting and expensive reflex testing for the effective cascade of care.
Funding Information
  • Abbott Laboratories

This publication has 11 references indexed in Scilit: